

Shionogi to Determine the Contents of Stock Options as Compensation (Stock Acquisition Rights)

Osaka, Japan, July 7, 2017 - Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi” or “the Company”) today announced that it has decided on the contents of pending items of the stock acquisition rights, which was resolved at the meeting of the Board of Directors of the Company held on June 22nd, 2017. The decisions are detailed below.

1. Total number of the stock acquisition rights
193 units

2. Total number of persons offered the stock acquisition rights and number of stock acquisition rights
The Qualified Directors: 3 Directors, 85 units
The Corporate Officers: 12 Officers, 108 units

3. The amount to be paid for stock acquisition rights
¥ 574,100 per stock acquisition right (option value: ¥ 5,741 per share)
The amount paid shall be equal to the fair market value per stock acquisition rights on the allotment date as calculated using the Black-Scholes model.
The person to whom stock acquisition rights are allotted may offset the remuneration amount with payment debt of the stock acquisition rights to be issued.

4. The class and number of shares to be issued upon exercise of stock acquisition rights
Common stocks of Shionogi 19,300 shares

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For further information, contact:

Corporate Communications Department
Shionogi & Co., Ltd.

Telephone: +81-6-6209-7885 Fax: +81-6-6229-9596